Current Medical Research and Opinion最新文献

{"title":"What to expect in 2026-2027: important health economics and outcomes research topics.","authors":"Ivo Abraham, Mickael Hiligsmann, Kenneth K C Lee, Giorgio L Colombo, Leslie Citrome, Mike Gregg","doi":"10.1080/03007995.2026.2692753","DOIUrl":"10.1080/03007995.2026.2692753","url":null,"abstract":"","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1329-1337"},"PeriodicalIF":2.8,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148789303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Healthcare resource utilization and costs associated with a diagnosis of infectious mononucleosis in children, adolescents, and adults in the United States.","authors":"Mihaela Georgieva, Zheng Wang, Tianyi Lu, John Diaz-Decaro, Philip O Buck","doi":"10.1080/03007995.2026.2721835","DOIUrl":"10.1080/03007995.2026.2721835","url":null,"abstract":"<p><strong>Objective: </strong>Epstein-Barr virus (EBV) is responsible for 90% of infectious mononucleosis (IM) cases. Clinically, IM often presents with fever, fatigue, sore throat, and lymphadenopathy, but can also result in prolonged symptoms requiring hospitalization. As little is known about the impact of IM on healthcare resource utilization (HCRU) and costs in the US general population, we evaluated these outcomes following IM diagnosis in non-transplant children, adolescents, and adults.</p><p><strong>Methods: </strong>A retrospective analysis was conducted using Merative MarketScan Commercial Claims and Encounters and Multi-State Medicaid databases. Since the COVID-19 pandemic had a substantial impact on patterns of HCRU, separate pre-pandemic and pandemic time periods were analyzed. Non-transplant individuals aged 5-40 years with diagnosed IM were selected and matched 1:1 to controls.</p><p><strong>Results: </strong>For the pre-pandemic (pandemic) periods, 31,671 (17,341) commercial and 10,758 (6,597) Medicaid matched pairs were included. All-cause HCRU and costs during the 6-month follow-up were generally higher for diagnosed IM cases vs controls. Significantly greater mean total medical visits and outpatient visits, as well as significantly higher percentages of hospitalizations, were observed for commercially-insured and Medicaid-enrolled IM cases vs controls across both time periods. Median total medical costs were significantly higher for IM cases than controls for commercially-insured ($1,050 vs $516; $1,346 vs $570) and Medicaid-enrolled ($701 vs $419; $938 vs $537) cohorts during the pre-pandemic and pandemic periods, respectively.</p><p><strong>Conclusion: </strong>In broad population-based US cohorts, individuals with diagnosed IM had significantly higher HCRU and healthcare costs than matched controls. Preventative strategies, such as vaccination against EBV and/or IM, could help reduce disease burden.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1367-1377"},"PeriodicalIF":2.8,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148839370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term complications of traditional and novel management of groin hernia: a narrative review.","authors":"Jacob Rosenberg","doi":"10.1080/03007995.2026.2723580","DOIUrl":"10.1080/03007995.2026.2723580","url":null,"abstract":"<p><p>Groin hernia repair is among the most common surgical procedures worldwide, yet chronic postoperative pain and recurrence remain important long-term complications. This narrative review compares long-term outcomes after traditional open repair with minimally invasive laparoscopic approaches. Evidence was identified through a structured, non-systematic search of PubMed/MEDLINE and the Cochrane Library, supplemented by reference lists and current international guidelines. Laparoscopic repair is consistently associated with less acute and chronic postoperative pain than open mesh repair, while recurrence rates are broadly comparable when procedures are performed by adequately trained surgeons. However, laparoscopic repair has a steeper learning curve and outcomes are operator-dependent. Mesh-related complications, including seroma, infection, meshoma, and foreign body sensation, occur in a minority of patients but may substantially impair quality of life. Tissue-based repairs, particularly the Shouldice and Desarda techniques, remain valid options for selected patients in experienced hands. Robotic-assisted repair may offer ergonomic and educational advantages, but evidence of superior patient outcomes is limited, while operative times and costs are generally higher than with conventional laparoscopy. Population-level data suggest that greater use of minimally invasive techniques in high-volume centers is associated with improved patient-reported outcomes. Surgical planning should therefore be individualized according to patient sex, age, hernia characteristics, and surgeon expertise. Much of the available evidence is observational or registry-based rather than randomized, which should temper the strength of recommendations. Future priorities include exploring bioengineered mesh, genetic risk stratification, and the potential role of artificial intelligence in surgical decision-making, although these avenues remain at an early exploratory stage.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1473-1486"},"PeriodicalIF":2.8,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148825753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Managing the patient with hypertension and elevated heart rate in the routine care setting: expert opinion and narrative review.","authors":"Gianfranco Parati, Ashraf Amir, Khaled Refaat Abd El Meguid, Hani Sabbour, Chiara Centonze, Nqoba Tsabedze, Ghazi Farhan Haji, Anna Perminova, Ahmed Bennis, Natalia Koziolova, Atul Pathak","doi":"10.1080/03007995.2026.2682073","DOIUrl":"10.1080/03007995.2026.2682073","url":null,"abstract":"<p><p>Increased resting heart rate (RHR) due to overactivity of the sympathetic nervous system (SNS) increases the risk of adverse cardiovascular outcomes in hypertension by promoting multiple aspects of hypertension-mediated organ damage (HMOD) such as endothelial dysfunction, arterial stiffness, left ventricular hypertrophy and renal damage. A vicious cycle of SNS overactivity and adverse cardiovascular remodelling leads ultimately to increased risk of adverse clinical cardiovascular outcomes and heart failure with either reduced or preserved left ventricular ejection fraction. Epidemiological studies show that elevated RHR (>80 bpm) provides a straightforward means of identifying people with hypertension likely to be complicated by SNS overactivity who may benefit from therapy that reduces HR and/or the activity of the SNS, such as beta-blockers. The current (2023/2024) guideline from the European Society of Hypertension (ESH) provides detailed guidance on the management of arterial hypertension. Like other guidelines, this document is long and complex. An expert group of cardiologists from Europe, the Middle East, Africa, and Russia, with experience in the clinical handling of such patients, have summarised the key elements of the 2023 ESH guideline, for the identification and management of patients with hypertension driven by an overactive sympathetic nervous system. These recommendations are based on a detailed review of clinical evidence. They are intended to propose a straightforward, pragmatic approach aimed at supporting physicians' clinical practice in primary care and other routine care settings, including in higher-, medium-, and lower-income countries, and in rural and urban environments.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1093-1111"},"PeriodicalIF":2.8,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148419358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A quarter-century of montelukast: clinical lessons for adult and pediatric asthma and allergic rhinitis care.","authors":"Jan S Redfern, Megan A Smith","doi":"10.1080/03007995.2026.2700973","DOIUrl":"10.1080/03007995.2026.2700973","url":null,"abstract":"<p><p>Montelukast entered routine respiratory practice in the late 1990s and remains widely used for asthma, allergic rhinitis (AR), and exercise-induced bronchoconstriction (EIBC). Its continued use has been driven largely by once-daily oral administration, ease of implementation, broad indications, and perceived advantages in patients with poor adherence to or difficulty using inhaled therapies. However, over time, the role of montelukast has evolved as comparative efficacy data, long-term safety findings, and treatment guidelines have modified expectations regarding its clinical value. This review re-examines the contemporary role of montelukast <i>via</i> integrating evidence on its mechanism of action, comparative clinical efficacy, prescribing patterns, safety outcomes, and future directions for individualized therapy. Clinical evidence demonstrates measurable benefit across asthma, AR, and EIBC; however, treatment effects are generally modest and variable and typically inferior to inhaled corticosteroid (ICS)-based regimens or intranasal corticosteroids (INCS). Nevertheless, patients, with poor inhaler adherence, exercise-related symptoms, aspirin-exacerbated respiratory disease, concomitant AR, or preference for oral therapy, may derive clinically meaningful benefit. Post-marketing surveillance has altered the therapeutic positioning of montelukast. Recognition of infrequent, but potentially serious, neuropsychiatric adverse events culminated in strengthened regulatory warnings and more cautious prescribing practices. Current management, therefore, emphasizes patient selection, pre-treatment counseling, shared decision-making, monitoring for behavioral changes, and timely review of treatment response. Current guidelines generally position montelukast as an alternative or add-on controller rather than a preferred first-line therapy. In the future, advances in pharmacogenomics, biomarker development, and phenotype-guided treatment strategies may improve the identification of patients most likely to benefit from montelukast.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1179-1194"},"PeriodicalIF":2.8,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148469440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and economic impact on people with relapsing-remitting multiple sclerosis in the United States: a matched-cohort study.","authors":"Nupur Greene, Ashis K Das, Ines Hemim, Eunice Chang, Marian H Tarbox, Keiko Higuchi","doi":"10.1080/03007995.2026.2709407","DOIUrl":"10.1080/03007995.2026.2709407","url":null,"abstract":"<p><strong>Objectives: </strong>To understand the real-world clinical and economic impact of relapsing-remitting multiple sclerosis (RRMS) in the United States (US).</p><p><strong>Methods: </strong>This retrospective, matched-cohort study used a large, integrated US administrative health database from 01 January 2012 to 31 December 2021. People with RRMS (PwRRMS) were identified using a validated algorithm or through electronic health records and matched 1:1 to MS-free controls based on age, gender, race, region, and insurance. Demographics, comorbidities, healthcare resource utilization (HCRU), and healthcare costs (HCCs) were compared between the RRMS cohort and MS-free controls during 1-year follow-up. All costs were reported in 2021 US dollars.</p><p><strong>Results: </strong>The final cohort comprised 9,290 people (RRMS, <i>n</i> = 4,645; MS-free controls, <i>n</i> = 4,645) with a mean ± SD age of 52.9 ± 14.4 years; 79.1% were female. During the follow-up period, compared with the controls, the RRMS cohort had significantly higher prevalence of infections (60.9% vs. 51.5%; <i>p</i> < 0.001) and MS-related comorbidities, including malaise/fatigue (34.3% vs. 15.7%), major depressive disorders (27.6% vs. 17.7%), anxiety (21.4% vs. 15.1%), burning/numbness (19.4% vs. 5.8%), and abnormal gait (16.1% vs. 5.2%) (all <i>p</i> < 0.001). RRMS was associated with significantly higher mortality (5.0% vs. 1.2%), hospitalizations (18.2% vs. 11.5%), emergency department visits (40.3% vs. 28.1%), and physician visits (13.7 vs. 10.0) (all <i>p</i> < 0.001) versus controls. Mean total HCCs were significantly higher for RRMS versus controls ($54,244 vs. $19,671; <i>p</i> < 0.001), driven primarily by medical claims ($31,154 vs. $15,944; <i>p</i> < 0.001).</p><p><strong>Conclusions: </strong>PwRRMS experienced a greater impact of comorbidities and significantly increased HCRU and HCCs, highlighting the need to integrate these impacts into everyday clinical decision‑making.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1151-1163"},"PeriodicalIF":2.8,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148663615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cross-publisher agreement on the defining principles of plain language summaries of publications (PLSPs).","authors":"Sophie Nobes, Kelly Soldavin, Rachel Jenkins, Hamish McDougall, Joanne Walker, Laura Dormer, Vicky Sanders","doi":"10.1080/03007995.2026.2700975","DOIUrl":"10.1080/03007995.2026.2700975","url":null,"abstract":"<p><p>Introduced in 2020, plain language summaries of publications (PLSPs) are standalone articles that aim to expand the reach of scientific findings to non-specialist audiences using plain language and meaningful visuals. Despite increased publication, there is no agreed cross-publisher definition of PLSPs, resulting in inconsistent terminology, formatting, peer-review processes, and metadata that hinder indexing and discoverability in bibliographic databases such as PubMed and Europe PMC. In February 2024, the multistakeholder collaboration Open Pharma launched an initiative to review existing standards and practices related to the publication of PLSPs. After identifying three publishers offering standalone PLSPs - Becaris Publishing, Sage, and Taylor & Francis - representatives from each formed a steering committee to define PLSPs and agree on principles that differentiate them from other publishing formats. PLSPs are defined as standalone summaries of peer-reviewed articles, written according to plain language principles, published open access with a unique digital object identifier (DOI), and are themselves peer reviewed (including by someone who is not a scientific specialist in the topic area). They should include a summary, clear reference to the original article, and a combination of text and meaningful graphics. This consensus provides a foundation for standardizing PLSPs as a distinct article type and acceptable secondary publication format. We hope it will also support consistent authoring, editorial management, peer-review processes and indexing. We call on indexing services to formally recognize PLSPs and on publishers to adopt this format as an accurate and reliable source of understandable scientific information.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1269-1273"},"PeriodicalIF":2.8,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148454986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Initiating dextromethorphan-bupropion extended release in patients with major depressive disorder: Delphi panel expert consensus recommendations.","authors":"Anita H Clayton, Gus Alva, Phillip Bowman, Erin Crown, Bibi Das, Paul Doghramji, Brooke Kempf, Andrew Muzyk, Jeremy Schreiber, John J Miller","doi":"10.1080/03007995.2026.2700073","DOIUrl":"10.1080/03007995.2026.2700073","url":null,"abstract":"<p><strong>Objective: </strong>To establish consensus recommendations for initiating dextromethorphan-bupropion extended release (45 mg/105 mg) (AUVELITY) for the treatment of major depressive disorder (MDD) in adults.</p><p><strong>Methods: </strong>US-based healthcare providers (HCPs, <i>n</i> = 10) with clinical experience treating MDD participated in a 3-stage modified Delphi panel procedure. An initial literature review was performed to assist in the development of draft recommendation statements. The draft recommendations were discussed and revised in two live meetings, with a series of anonymous votes taken to reach consensus for each proposed statement. Recommendations required a mean score ≥3.0 (75% agreement) to reach consensus.</p><p><strong>Results: </strong>The panel reached consensus on 27 final recommendations with a mean overall agreement score of 3.8. Key consensus recommendations (abbreviated here) included: (1) dextromethorphan-bupropion is recommended as a first-line treatment for MDD, including with co-occurring symptoms of anxiety; (2) HCPs should individualize treatment decisions that prioritize safety considerations noted in the Prescribing Information; (3) dextromethorphan-bupropion is recommended for patients with inadequate response, residual symptoms, and/or intolerable side effects associated with prior MDD treatment(s); (4) when switching from (or adding to current) medication, the potential for a drug interaction should be considered, consistent with the dextromethorphan-bupropion label; and (5) switching from ketamine or esketamine should be done with caution, and with an awareness of the short-to-intermediate elimination half-lives of these drugs.</p><p><strong>Conclusion: </strong>These consensus panel recommendations provide real-world guidance for initiating MDD treatment with dextromethorphan-bupropion extended release and address any perceived barriers for scenarios of interest.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1243-1256"},"PeriodicalIF":2.8,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148444930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring preferences of patients, care partners, and prescribers for an injectable antipsychotic administered once every 2 months for treatment of schizophrenia: a plain language summary.","authors":"Murat Yildirim, Kristine Harrsen, Soma Nag, Xavier Guillaume, Roger S McIntyre, Sofia Pappa","doi":"10.1080/03007995.2026.2695146","DOIUrl":"10.1080/03007995.2026.2695146","url":null,"abstract":"","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1257-1268"},"PeriodicalIF":2.8,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148430034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-effectiveness of nasal adrenaline in the treatment of anaphylaxis.","authors":"Shuaib Nasser, Luca Bottazzi, Andrea Lang, Rebecca Skou, Anne Danø, Peter Carlqvist","doi":"10.1080/03007995.2026.2700046","DOIUrl":"10.1080/03007995.2026.2700046","url":null,"abstract":"<p><strong>Background: </strong>Nasal adrenaline spray is a novel needle-free alternative for the emergency treatment of anaphylaxis. Evidence on its cost-effectiveness versus adrenaline auto-injectors (AAIs) is currently limited. This analysis evaluates the cost-effectiveness of the nasal adrenaline spray versus an AAI in individuals ≥ 30 kg (approximately 8 years of age) at risk of all-cause anaphylaxis in the United Kingdom (UK).</p><p><strong>Methods: </strong>A <i>de novo</i> Markov cohort model was developed for the UK setting from a societal perspective over a lifetime horizon. Four health states captured the risks and consequences of anaphylaxis. Clinical inputs included the probability of initial and recurrent anaphylactic episodes, adrenaline carriage, whether used, administration accuracy and needle-related administration errors. Costs included product acquisition, training, emergency care, hospitalization, needle-related administration errors, and productivity loss. Outcomes were quality-adjusted life years (QALYs), with costs and benefits discounted at 3.5% annually. The impact of uncertainty was assessed using deterministic and probabilistic sensitivity analyses.</p><p><strong>Results: </strong>In the base case, the nasal adrenaline spray was dominant versus the AAI, yielding 0.26 additional QALYs at a lower cost (-£681). Cost differences were mainly driven by product acquisition, hospitalization rates and productivity loss. Results were robust across scenario analyses but were sensitive to assumptions about adrenaline carriage and use.</p><p><strong>Conclusions: </strong>In the UK, the nasal adrenaline spray may be a cost-effective alternative to AAIs, largely due to assumed higher carriage and greater likelihood of use during anaphylactic episodes. Further real-world evidence is needed to validate these assumptions and their impact on cost-effectiveness.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1195-1205"},"PeriodicalIF":2.8,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148469453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}